J. Mahlangu

发表

Gene and cell therapy in South Africa: Current status and future prospects.

M. Pepper, A. Ely, K. Bloom, 2019, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi‐centre, non‐interventional study

J. Oldenburg, E. Santagostino, M. Recht, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors

J. Mahlangu, 2018, BioDrugs.

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.

V. Ramanan, P. Mannucci, F. Rosendaal, 2016, The New England journal of medicine.

Key issues in inhibitor management in patients with haemophilia.

M. Ozelo, J. Mahlangu, R. Klamroth, 2014, Blood transfusion = Trasfusione del sangue.

Guidelines for the management of hemophilia

J. Mahlangu, N. Key, M. Poon, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Phase I, randomized, double‐blind, placebo‐controlled, single‐dose escalation study of the recombinant factor VIIa variant BAY 86‐6150 in hemophilia

M. Laffan, J. Mahlangu, J. Windyga, 2012, Journal of thrombosis and haemostasis : JTH.

Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4).

J. Oldenburg, A. Chuansumrit, E. Santagostino, 2016, Thrombosis research.

Kaposi Sarcoma-Associated Herpesvirus/Human Herpesvirus 8 and Multiple Myeloma in South Africa

J. Mahlangu, W. Stevens, W. Stevens, 2001, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Emerging therapies for haemophilia ‐ Global perspective

J. Mahlangu, A. Srivastava, M. Cerquiera, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

S. Lethagen, M. Laffan, J. Mahlangu, 2015, Journal of thrombosis and haemostasis : JTH.

Deep-vein thrombosis in the era of high HIV and tuberculosis prevalence: A prospective review of its diagnosis and treatment in a quaternary centre.

J. Mahlangu, K. Hodkinson, 2017, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors

A. al‐Sabbagh, C. Hermans, C. Leissinger, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Diagnosis of iron deficiency anaemia in hospital patients: Use of the reticulocyte haemoglobin content to differentiate iron deficiency anaemia from anaemia of chronic disease.

J. Mahlangu, E. Schapkaitz, S. Buldeo, 2015, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

A cohort study of the relationship between anaemia, mean corpuscular volume and mortality among a CKD population in South Africa

J. Mahlangu, S. Naicker, R. Duarte, 2021, African Health Sciences.

Utility of reticulocyte haemoglobin content and percentage hypochromic red cells as markers of iron deficiency anaemia among black CKD patients in South Africa

J. Mahlangu, S. Naicker, R. Duarte, 2018, PloS one.

Requirements to participate in haemophilia clinical trials

J. Mahlangu, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Low‐factor consumption for major surgery in haemophilia B with long‐acting recombinant glycoPEGylated factor IX

P. Giangrande, R. Tehranchi, J. Mahlangu, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.

E. Santagostino, L. Boggio, K. Fischer, 2016, Blood.

Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial

A. Chuansumrit, M. Morfini, J. Mahlangu, 2012, Journal of thrombosis and haemostasis : JTH.

Emicizumab state‐of‐the‐art update

A. Iorio, J. Mahlangu, G. Kenet, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A

J. Oldenburg, J. Mahlangu, R. Klamroth, 2016, Thrombosis and Haemostasis.

Patient blood management: A solution for South Africa.

J. Mahlangu, C. Lundgren, C. Hilton, 2019, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Hepcidin and GDF-15 are potential biomarkers of iron deficiency anaemia in chronic kidney disease patients in South Africa

J. Mahlangu, S. Naicker, T. Snyman, 2019, BMC Nephrology.

Genotype-phenotype correlation in combined deficiency of factor V and factor VIII.

P. Platzer, R. Kaufman, D. Ginsburg, 2008, Blood.

Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10‐year survey

J. Mahlangu, P. James, P. Holme, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

The evolving landscape of gene therapy for congenital haemophilia: An unprecedented, problematic but promising opportunity for worldwide clinical studies.

N. Brunetti‐Pierri, A. Di Minno, J. Mahlangu, 2020, Blood reviews.

Non‐factor therapies for bleeding disorders: A primer for the general haematologist

J. Thachil, J. Mahlangu, D. Swan, 2022, EJHaem.

Once‐weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9‐GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials

J. Oldenburg, M. Carcao, C. Négrier, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.

K. Fischer, J. Mahlangu, B. Nolan, 2017, The Lancet. Haematology.

Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A

J. Mahlangu, R. Liesner, B. Nolan, 2015, Journal of thrombosis and haemostasis : JTH.

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.

M. Ozelo, D. Quon, A. Leavitt, 2022, The New England journal of medicine.

Haemophilia gene therapy—Update on new country initiatives

T. Ohmori, M. Ozelo, J. Mahlangu, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII.

C. Kempton, C. Kessler, B. Ritchie, 2007 .

Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study

J. Oldenburg, M. Ozelo, M. Trossaërt, 2021, Journal of Clinical Medicine.

HAEMOcare: The First International Epidemiological Study Measuring Burden of Hemophilia in Developing Countries

J. Mahlangu, S. Benchikh El Fegoun, Y. Wali, 2019, TH Open.

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity

M. Recht, S. Kaicker, J. Mahlangu, 2015, Journal of thrombosis and haemostasis : JTH.

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa

J. Mahlangu, T. Matsushita, J. Windyga, 2014, Journal of thrombosis and haemostasis : JTH.

Underdiagnosis of iron deficiency anaemia in HIV-infected individuals: a pilot study using soluble transferrin receptors and intensive bone marrow iron stores to improve the diagnosis

J. Mahlangu, E. Variava, N. Martinson, 2022, Journal of Clinical Pathology.

Hemophilia gene therapy knowledge and perceptions: Results of an international survey

A. Srivastava, K. Pasi, J. Mahlangu, 2020, Research and practice in thrombosis and haemostasis.

Myocardial infarction in severe haemophilia

J. Mahlangu, J. Bailly, 2018 .

Evaluation of the self‐administered bleeding assessment tool (Self‐BAT) in haemophilia carriers and correlations with quality of life

J. Mahlangu, P. James, W. Hopman, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Recombinant factor IX‐Fc fusion protein in severe hemophilia B: Patient‐reported outcomes and health‐related quality of life

J. Mahlangu, N. O'Connell, E. Singleton, 2021, Research and practice in thrombosis and haemostasis.

The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial

P. Arkhammar, J. Mahlangu, S. Rangarajan, 2016, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies

V. Jiménez‐Yuste, J. Mahlangu, S. Pipe, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Thrombotic thrombocytopenic purpura: A 5‐year tertiary care centre experience

J. Mahlangu, L. Swart, E. Schapkaitz, 2018, Journal of clinical apheresis.

A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia

Michael Wang, L. Boggio, J. Mahlangu, 2022, British journal of haematology.

Pharmacokinetic modelling and validation of the half‐life extension needed to reduce the burden of infusions compared with standard factor VIII

C. Hermans, E. Santagostino, V. Blanchette, 2018, Haemophilia.

Point-of-care estimation of haemoglobin concentration in all age groups in clinical practice

J. Mahlangu, E. Schapkaitz, 2011 .

Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein

J. Dumont, J. Oldenburg, V. Blanchette, 2018, Haemophilia.

Unexplained hemorrhagic syndrome? Consider acquired hemophilia A or B.

S. Pașca, D. Coriu, J. Mahlangu, 2021, Blood reviews.

Leave no one behind: Optimal Care of all Patients with Haemophilia A.

J. Mahlangu, 2022, JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA.

Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors

C. Hermans, Michael Wang, M. Carcao, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Long-term outcomes with emicizumab prophylaxis for hemophilia A with/without FVIII inhibitors from the HAVEN 1-4 studies.

J. Oldenburg, V. Jiménez‐Yuste, S. Chebon, 2020, Blood.

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

J. Oldenburg, V. Jiménez‐Yuste, C. Kempton, 2018, The New England journal of medicine.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

J. Oldenburg, E. Santagostino, C. Kessler, 2017, The New England journal of medicine.

Haemophilia management: time to get personal?

C. Yanover, J. Mahlangu, A. Krause, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

WFH Guidelines for the Management of Hemophilia, 3rd edition

E. Santagostino, M. Carcao, B. Feldman, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Optimising musculoskeletal care for patients with haemophilia

E. Santagostino, M. Carcao, J. Mahlangu, 2015, European journal of haematology.

Assessment of outcomes

V. Blanchette, J. Mahlangu, B. O’Mahony, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years

E. Santagostino, J. Mahlangu, S. Lalezari, 2020, European journal of haematology.

Redefining prophylaxis in the modern era

V. Blanchette, J. Mahlangu, R. Klamroth, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.

J. Oldenburg, V. Jiménez‐Yuste, Michael Wang, 2019, Blood.

Home therapy for inherited bleeding disorders in South Africa: Results of a modified Delphi consensus process.

A. Iorio, J. Mahlangu, J. Joubert, 2019, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study

J. Oldenburg, E. Santagostino, B. Konkle, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

rFVIIIFC for hemophilia A prophylaxis

J. Mahlangu, 2018, Expert review of hematology.

Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors

J. Mahlangu, 2018, BioDrugs.

Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B

J. Mahlangu, 2018, Therapeutic advances in hematology.

Defining extended half‐life rFVIII—A critical review of the evidence

C. Hermans, E. Santagostino, V. Blanchette, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Miguel Ángel Martínez, P. Mannucci, E. Santagostino, 2015 .

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.

J. Oldenburg, C. Négrier, J. Mahlangu, 2014, Blood.

Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.

J. Oldenburg, C. Hermans, V. Jiménez‐Yuste, 2023, The Lancet. Haematology.

Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B.

J. Oldenburg, D. Perry, M. Ozelo, 2016, Thrombosis and haemostasis.

Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein ( rFIXFc ) in subjects with haemophilia

J. Oldenburg, D. Perry, M. Ozelo, 2017 .

Clinical haemophilia Long-term safety and efficacy of recombinant factor VIII Fc fusion protein ( rFVIIIFc ) in subjects with haemophilia

D. Perry, B. Konkle, K. Pasi, 2016 .

Long-Term Safety and Efficacy of Recombinant Factor VIII FC (RFVIIIFC) in Adults and Adolescents With Severe Haemophilia A: An Interim Analysis of The ASPIRE Study

D. Perry, B. Konkle, J. Mahlangu, 2015 .

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies

J. Oldenburg, V. Jiménez‐Yuste, S. Chebon, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

J. Dumont, D. Perry, L. Valentino, 2013, The New England journal of medicine.

Long‐acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B‐LONG study

C. Hermans, D. Perry, M. Ozelo, 2015, British journal of haematology.

Long-lasting recombinant factor FIX Fc fusion (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study

C. Hermans, H. Chambost, J. Mahlangu, 2013 .

Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels

J. Dumont, I. Nestorov, D. Quon, 2014, Journal of thrombosis and haemostasis : JTH.

PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors

J. Luck, A. al‐Sabbagh, C. Hermans, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

J. Dumont, I. Nestorov, D. Perry, 2014, Blood.

Efficacy and safety of long‐acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery

E. Santagostino, A. Lienhart, C. Négrier, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing

J. Mahlangu, S. Pipe, M. Mancuso, 2021, The Lancet.

The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study

J. Oldenburg, E. Santagostino, C. Kessler, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A‐LONG study subjects with severe haemophilia A

D. Perry, D. Quon, J. Mahlangu, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study

J. Oldenburg, M. Ozelo, H. Chambost, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Changes in health‐related quality of life with treatment of longer‐acting clotting factors: results in the A‐LONG and B‐LONG clinical studies

K. Wyrwich, J. Mahlangu, S. Krishnan, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Guideline for the treatment of haemophilia in South Africa.

J. Mahlangu, A. Gilham, 2008, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Global Emerging HEmophilia Panel (GEHEP): A Multinational Collaboration for Advancing Hemophilia Research and Treatment

J. Mahlangu, M. Mancuso, R. Kruse-Jarres, 2013, Transfusion Medicine and Hemotherapy.

HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors

J. Oldenburg, J. Mahlangu, R. Liesner, 2017 .

Emicizumab for the prevention of bleeds in hemophilia A

J. Mahlangu, 2019, Expert opinion on biological therapy.

Dental management of patients with inherited bleeding disorders: a retrospective study

J. Mahlangu, Sponono Mahlangu, S. Shangase, 2018 .

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors

C. Kempton, J. Mahlangu, N. O'Connell, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study

J. Oldenburg, V. Jiménez‐Yuste, E. Santagostino, 2020, Pediatric blood & cancer.

Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3

V. Jiménez‐Yuste, C. Kempton, C. Kessler, 2022, Research and practice in thrombosis and haemostasis.

J. Oldenburg, V. Jiménez‐Yuste, S. Chebon, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non‐interventional study in a real‐world setting

J. Oldenburg, E. Santagostino, C. Kempton, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

D. Perry, B. Konkle, K. Pasi, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B

J. Mahlangu, Martin L Lee, H. Levy, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies

M. Ozelo, S. Lethagen, K. Pasi, 2022, Research and practice in thrombosis and haemostasis.

Long‐term safety and efficacy of the anti‐tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results

J. Mahlangu, S. Arkin, J. Teeter, 2022, British journal of haematology.

Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table

A. Weill, T. Sannié, K. Pasi, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH

M. Carcao, A. Tosetto, J. Mahlangu, 2018, Journal of thrombosis and haemostasis : JTH.

BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review

J. Mahlangu, J. Windyga, S. Ahuja, 2018, Therapeutic advances in hematology.

Extended half‐life clotting factor concentrates: results from published clinical trials

J. Mahlangu, G. Young, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Improving access to hemophilia care in sub-Saharan Africa by capacity building.

J. Mahlangu, S. Kitchen, G. Pierce, 2019, Blood advances.

J. Oldenburg, J. Mahlangu, M. Mancuso, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

J. Oldenburg, M. Recht, J. Mahlangu, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

An update of the current pharmacotherapeutic armamentarium for hemophilia A

J. Mahlangu, 2021, Expert opinion on pharmacotherapy.

Haemophilia care in South Africa: 2004–2007 look back

J. Mahlangu, J. Mahlangu, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study

J. Oldenburg, C. Négrier, J. Mahlangu, 2017 .

Safety, efficacy and pharmacokinetics of nonacog beta pegol (N9-GP) for prophylaxis and treatment of bleeding episodes in patients with haemophilia B

J. Oldenburg, C. Négrier, J. Mahlangu, 2013 .

Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients

J. Mahlangu, A. Krause, A. Lochan, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database

P. Kuebler, J. Mahlangu, S. Pipe, 2020, Journal of thrombosis and haemostasis : JTH.

A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH

M. Othman, J. Mahlangu, P. James, 2021, Journal of thrombosis and haemostasis : JTH.

Evaluation of the utility of the ISTH‐BAT in haemophilia carriers: a multinational study

J. Mahlangu, P. James, W. Hopman, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A

J. Oldenburg, B. Konkle, K. Pasi, 2018, Blood.

World Federation of Hemophilia Gene Therapy Registry

A. Iorio, B. Konkle, B. Tortella, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database

P. Kuebler, J. Mahlangu, S. Pipe, 2020, Journal of thrombosis and haemostasis : JTH.

TRUST trial: BAY 86‐6150 use in haemophilia with inhibitors and assessment for immunogenicity

J. Mahlangu, J. Schroeder, M. Hardtke, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety

J. Mahlangu, G. Iosava, B. Korczowski, 2021, Research and practice in thrombosis and haemostasis.

Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII FC Fusion Protein (RFVIIIFC) in Previously Treated Paediatric Subjects with Severe Haemophilia A (Kids A-LONG)

J. Mahlangu, B. Nolan, G. Young, 2013 .

Seroprevalence of Pre-Existing Nabs Against AAV1, 2, 5, 6 and 8 in South African Hemophilia B Patient Population

Valérie Ferreira, S. V. van Deventer, J. Mahlangu, 2019, Blood.

Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

J. Oldenburg, C. Hermans, V. Jiménez‐Yuste, 2021, Blood.

Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study

J. Oldenburg, V. Jiménez‐Yuste, Michael Wang, 2018, Blood.

Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting

J. Oldenburg, E. Santagostino, S. Chebon, 2017 .

Interim Analysis Of The ASPIRE Study Evaluating Long-term Safety And Efficacy Of Recombinant Factor VIII FC (RFVIIIFC) In Children With Severe Haemophilia A

J. Mahlangu, B. Nolan, G. Young, 2015 .

Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously-Treated Children with Severe Hemophilia a (Kids-ALONG)

J. Mahlangu, B. Nolan, G. Young, 2014 .

Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study of the rFVIIa Variant (BAY 86–6150) In Hemophilia A or B with or without Inhibitors.

M. Laffan, J. Mahlangu, J. Windyga, 2010 .

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial

J. Oldenburg, A. Chuansumrit, E. Santagostino, 2014 .

Recombinant single‐chain factor VIII in severe hemophilia: Long‐term safety and efficacy in previously treated patients in the AFFINITY extension study

J. Mahlangu, O. Stasyshyn, I. Pabinger, 2022, Research and practice in thrombosis and haemostasis.

Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A

J. Oldenburg, M. Ozelo, D. Quon, 2022, Human gene therapy.

Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management

J. Mahlangu, 2021, Frontiers in Medicine.

Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies

J. Oldenburg, V. Jiménez‐Yuste, S. Chebon, 2018, Blood.

Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing "Empty Viral Particles" on Safety and Efficacy of Gene Transfer

A. Nienhuis, C. Morton, A. Davidoff, 2018, Blood.

Uptake of Genetic Counseling, Knowledge of Bleeding risks and Psychosocial Impact in a South African Cohort of Female Relatives of People with Hemophilia

J. Mahlangu, A. Krause, Tina-Marié Wessels, 2015, Journal of Genetic Counseling.

B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B

J. Oldenburg, K. Pasi, K. Fischer, 2018, Blood.

Recombinant B‐domain‐deleted porcine sequence factor VIII (r‐pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors

J. Mahlangu, N. Key, C. Walsh, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Long-Term Safety and Efficacy of rFVIIIFc in Adults and Adolescents with Severe Hemophilia A: A Longitudinal Analysis of A-LONG and ASPIRE

D. Perry, B. Konkle, K. Pasi, 2015 .

factor VIII Genotype-phenotype correlation in combined deficiency of factor V and

P. Platzer, R. Kaufman, J. Mahlangu, 2011 .

Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH

A. Iorio, B. Konkle, J. Mahlangu, 2020, Journal of thrombosis and haemostasis : JTH.

Access to Systemic Anticancer Treatment and Radiotherapy Services in Sub-Saharan Africa

J. Mahlangu, V. Kunene, 2017 .

MOLECULAR ANALYSIS IN BURKITT'S LYMPHOMA

J. Mahlangu, 2008 .

A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia.

B. Pace, J. Mahlangu, S. Unal, 2022, Blood.

Guidelines for the treatment of myelodysplastic syndromes (MDS) in South Africa.

P. Ruff, J. Mahlangu, E. Verburgh, 2011, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Haemophilia clinical care and research needs: Assessing priorities

A. Iorio, C. Kessler, J. Mahlangu, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Hepatitis C virus genotypes in two different patient cohorts in Johannesburg, South Africa

A. Puren, J. Mahlangu, N. Prabdial-Sing, 2008, Archives of Virology.

Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa.

A. Puren, J. Blackard, J. Mahlangu, 2016, Antiviral research.

Ethnic prevalence of anemia and predictors of anemia among chronic kidney disease patients at a tertiary hospital in Johannesburg, South Africa

J. Mahlangu, S. Naicker, R. Duarte, 2019, International journal of nephrology and renovascular disease.

Local reference ranges for full blood count and CD4 lymphocyte count testing.

J. Mahlangu, W. Stevens, P. Becker, 2009, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Immunoglobulin subtyping and quantification in direct antiglobulin test: positive haemolysis in an HIV-prevalent setting

J. Mahlangu, N. Bouwer, Y. Wan, 2020, Journal of Clinical Pathology.

Palindromic-nucleotide substitutions (PNS) of hepatitis C virus genotypes 1 and 5a from South Africa.

A. Puren, J. Mahlangu, N. Prabdial-Sing, 2011, Journal of virological methods.

Pharmacokinetics, Safety, and Efficacy Of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Adolescent Subjects With Hemophilia B: A Subgroup Analysis Of The B-LONG Study

D. Perry, L. Valentino, M. Ozelo, 2013 .

Interim Analysis of the Extension Study with rVIII-SingleChain in Previously Untreated Patients (PUPs) with Severe Hemophilia A (CSL627-3001)

E. Santagostino, K. Fischer, J. Mahlangu, 2019, Blood.

Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and India

K. Cornetta, J. Mahlangu, S. Rangarajan, 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

Double-Blind, Randomized Study of Canakinumab Treatment in Pediatric and Young Adult Patients with Sickle Cell Anemia

B. Pace, J. Mahlangu, S. Unal, 2019, Blood.

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.

J. Oldenburg, M. Ozelo, D. Quon, 2023, The New England journal of medicine.

Prophylaxis is the new standard of care in patients with haemophilia.

J. Mahlangu, D. Reynders, B. Rayner, 2022, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Three‐way comparison of methods for the measurement of the erythrocyte sedimentation rate

J. Mahlangu, Melony Davids, 2008, Journal of clinical laboratory analysis.

Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)

J. Mahlangu, Depei Wu, C. Truica, 2015, Journal of thrombosis and haemostasis : JTH.

Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis

C. Kempton, C. Kessler, J. Mahlangu, 2023, Research and practice in thrombosis and haemostasis.

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

D. Quon, H. Chambost, M. Laffan, 2023, GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark.

Safety and Preliminary Efficacy of Recombinant Activated FVII Analog (NN1731) In the Treatment of Joint Bleeds In Congenital Hemophilia Patients with Inhibitors

A. Chuansumrit, M. Morfini, J. Mahlangu, 2010 .

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.

E. Santagostino, L. Boggio, K. Fischer, 2016, Blood.

Title Endogenous factor VIII synthesis from the intron 22-inverted F 8 locus may modulate the immunogenicity of replacement therapy for hemophilia

Yasmin, C. Yanover, T. Przytycka, 2014 .

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults

V. Blanchette, C. Négrier, S. Lethagen, 2023, Research and practice in thrombosis and haemostasis.

TMPRSS6 rs855791 polymorphism and susceptibility to iron deficiency anaemia in non-dialysis chronic kidney disease patients in South Africa.

J. Mahlangu, S. Naicker, R. Duarte, 2019, International journal of molecular epidemiology and genetics.

RNA sequencing suggests that non‐coding RNAs play a role in the development of acquired haemophilia

J. Bergthórsson, Alina-Andreea Zimta, D. Coriu, 2023, Journal of cellular and molecular medicine.